The migraine treatment market is experiencing significant advancements driven by the latest methods and technologies. Innovations such as neuromodulation devices, CGRP inhibitors, and personalized medicine are reshaping treatment approaches. These developments not only enhance efficacy but also improve patient outcomes and quality of life. The market's growth is fueled by rising awareness, increasing prevalence of migraines, and robust investments in research and development. As technology evolves, there's a promising shift towards more targeted and effective therapies, marking a transformative period in migraine management.
Data Bridge Market Research analyses that the Global Migraine Treatment Market size was valued at USD 2.38 billion in 2021, is projected to reach USD 4.67 billion by 2029, and is expected to undergo a CAGR of 8.80% during the forecast period 2022 to 2029.
To know more about the study, visit: https://www.databridgemarketresearch.com/reports/global-migraine-treatment-market
Below are the Top Five Migraine Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Amgen Inc.
|
Amgen has a strong presence in the migraine treatment market with its product Aimovig (erenumab), a CGRP inhibitor. Aimovig is used for the preventive treatment of migraine in adults and has been pivotal in advancing migraine care by targeting specific pathways involved in migraine pathophysiology. Amgen continues to invest in research and development to expand its portfolio in neurology, aiming to provide innovative therapies for migraine sufferers globally.
|
|
Asia-Pacific Europe, South America, North America, Middle East, and Africa
|
In December 2018, Amgen Inc. announced a multiyear collaboration with Magellan Rx Management. They have collaborated to evaluate the impacts of interventions in patients with migraine and osteoporosis. This collaboration has created value insights for patients and providers across healthcare systems.
|
|
2.
|
Eli Lilly and Company
|
Eli Lilly entered the migraine treatment market with Emgality (galcanezumab), another CGRP inhibitor used for the preventive treatment of migraine in adults. Emgality has demonstrated efficacy in reducing migraine frequency and severity, contributing significantly to Eli Lilly's neurology portfolio. The company focuses on developing therapies that address the unmet needs of migraine patients, leveraging its expertise in biotechnology to advance treatments for neurological disorders such as migraine.
|
|
Asia-Pacific Europe, South America, Latin America, North America, Australasia
|
In January 2020, Eli Lilly and Company announced that REYVOW C-V, 50 mg and 100 mg tablets is now available as an oral medication for the acute treatment of migraine in adults is now available by prescription. This product availability is going to increase the company’s product portfolio and hence add to its sales.
|
|
3.
|
GSK plc.
|
GSK has made strides in the migraine treatment market with its product Nucala (mepolizumab), initially approved for severe eosinophilic asthma but under investigation for potential efficacy in treating refractory chronic migraine. GSK aims to explore new therapeutic avenues in neurology and expand its presence in migraine treatment through innovative approaches and strategic partnerships.
|
|
Middle East, Asia, Africa, Europe, South and Central America, North America, Australasia
|
In March 2020, GlaxoSmithKline plc. announced that the U.S. FDA has approved Advil Dual Action with acetaminophen as an over-the-counter product for pain relief. Acetaminophen is used for making migraine treatment drugs. This approval has helped the company to strengthen its pain relief product portfolio and hence add on to its revenue.
|
|
4.
|
Novartis AG
|
Novartis has a robust presence in the migraine treatment market with its CGRP inhibitor products, including Aimovig (developed with Amgen) and more recently, Qulipta (fremanezumab). Qulipta is approved for the preventive treatment of migraine in adults and adds to Novartis' comprehensive portfolio in neurology. The company emphasizes personalized medicine and continues to invest in research to develop targeted therapies that address the diverse needs of migraine patients worldwide.
|
(Neuroscience)
|
Europe, America, Middle East and Africa, and Asia-Pacific
|
In April 2020, Novartis AG announced the clinical data for aimovig that was reported in neurology. This data confirms the real-world and long term efficacy of benefits of aimovig in patients with episodic and chronic migraine. This data has strengthened the aimovig efficacy and proved it to be an effective migraine solution which helped the company to increase its brand sale in the upcoming years.
|
|
5.
|
Bayer AG
|
Bayer is actively involved in the migraine treatment market with its product Aimovig (developed with Amgen) and recently launched Vyepti (eptinezumab), a CGRP inhibitor for the preventive treatment of migraine in adults. Bayer aims to expand its neurology portfolio and improve patient outcomes through innovative therapies that target migraine pathophysiology. The company's strategic focus on neurology underscores its commitment to addressing the significant burden of migraine on patients' lives globally.
|
|
Middle East, Latin America, North America, Africa, Europe, Asia, Australia, New Zealand
|
In February 2020, Bayer AG entered into definitive agreement to transfer its Berlin- based small molecule research unit to Nuvisan. As Bayer provides migraine solution, this research unit transfer to Nuvisan which has helped Bayer AG to expand its market of migraine treatment drugs.
|
Conclusion
The migraine treatment market is poised for substantial growth driven by increasing awareness, rising prevalence of migraine disorders globally, and advancements in therapeutic options. Key drivers such as expanding healthcare infrastructure, innovative drug development, and growing patient demand for effective treatments present significant opportunities for market expansion. With ongoing research focusing on personalized medicine and novel therapies, the future holds promise for enhanced outcomes and quality of life for migraine sufferers. Stakeholders in the pharmaceutical and healthcare sectors are positioned to capitalize on these trends, contributing to a dynamic and evolving landscape in migraine treatment.
